CancerNetwork® spoke with Nazli Dizman, MD, a hematology/oncology fellow at The University of Texas MD Anderson Cancer Center, about the potential of CBM588 in improving clinical outcomes for patients with metastatic renal cell carcinoma (RCC) receiving immune checkpoint inhibitors (ICIs). The analysis included findings from two studies: one evaluating nivolumab plus ipilimumab with CBM588 (NCT03829111) and another evaluating nivolumab plus cabozantinib with CBM588 (NCT05122546).
Dizman expressed optimism about elucidating the mechanism of action for CBM588 and hopes to observe improvements in clinical outcomes following the completion of a planned phase 3 trial. This trial aims to evaluate the clinical activity and gut microbiome modulation capacity of CBM588 combined with ICIs in patients with metastatic RCC receiving frontline ICI combinations.
The analysis involved 39 patients who received standard-of-care (SOC) therapy in combination with CBM588 and 20 others who received SOC alone. Stool samples were analyzed for gut biome diversity and composition at baseline and 12 weeks. Results indicated that CBM588 treatment was associated with a notable correction of gut dysbiosis and prevention of depletion of ICI response-associated species, suggesting a plausible mechanism for enhanced clinical outcome with the experimental therapy.
Dizman presented these findings at the 2024 Kidney Cancer Research Summit (KCRS), emphasizing the importance of lifestyle interventions, alternative biotherapeutics, and fecal microbiota transplant (FMT) for potentially improving patient outcomes.
